Global use of peripheral blood vs bone marrow as source of stem cells for allogeneic transplantation in patients with bone marrow failure

• Autores: Ayami Yoshimi, Helen Baldomero, Mary Horowitz
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 2, 2016, págs. 198-200
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many patients with bone marrow failure.1 Bone marrow was initially the only stem cell source available until the 1990s when peripheral blood stem cells (PBSCs) and cord blood began to be used.

    Currently, PBSCs are the major stem cell source,2 owing to faster engraftment and ease of collection despite a higher rate of graft-vs-host disease and lower survival rates in patients with nonmalignant disorders.